Home >> Research Area >>Natural Products>>Diterpenoids>> 15,16-Dihydrotanshindiol B

15,16-Dihydrotanshindiol B

CAS# 891854-86-7

15,16-Dihydrotanshindiol B

2D Structure

Catalog No. BCN3213----Order now to get a substantial discount!

Product Name & Size Price Stock
15,16-Dihydrotanshindiol B: 5mg Please Inquire In Stock
15,16-Dihydrotanshindiol B: 10mg Please Inquire In Stock
15,16-Dihydrotanshindiol B: 20mg Please Inquire Please Inquire
15,16-Dihydrotanshindiol B: 50mg Please Inquire Please Inquire
15,16-Dihydrotanshindiol B: 100mg Please Inquire Please Inquire
15,16-Dihydrotanshindiol B: 200mg Please Inquire Please Inquire
15,16-Dihydrotanshindiol B: 500mg Please Inquire Please Inquire
15,16-Dihydrotanshindiol B: 1000mg Please Inquire Please Inquire
Related Products

Quality Control of 15,16-Dihydrotanshindiol B

3D structure

Package In Stock

15,16-Dihydrotanshindiol B

Number of papers citing our products

Chemical Properties of 15,16-Dihydrotanshindiol B

Cas No. 891854-86-7 SDF Download SDF
PubChem ID 102004773 Appearance Red powder
Formula C18H18O5 M.Wt 314.3
Type of Compound Diterpenoids Storage Desiccate at -20°C
Solubility Soluble in Chloroform,Dichloromethane,Ethyl Acetate,DMSO,Acetone,etc.
Chemical Name (6R,7S)-6,7-dihydroxy-1,6-dimethyl-2,7,8,9-tetrahydro-1H-naphtho[1,2-g][1]benzofuran-10,11-dione
SMILES CC1COC2=C1C(=O)C(=O)C3=C2C=CC4=C3CCC(C4(C)O)O
Standard InChIKey HSWJBFKCVPRBJO-AJJMNOOBSA-N
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
We recommend that you prepare and use the solution on the same day. However, if the test schedule requires, the stock solutions can be prepared in advance, and the stock solution must be sealed and stored below -20℃. In general, the stock solution can be kept for several months.
Before use, we recommend that you leave the vial at room temperature for at least an hour before opening it.
About Packaging 1. The packaging of the product may be reversed during transportation, cause the high purity compounds to adhere to the neck or cap of the vial.Take the vail out of its packaging and shake gently until the compounds fall to the bottom of the vial.
2. For liquid products, please centrifuge at 500xg to gather the liquid to the bottom of the vial.
3. Try to avoid loss or contamination during the experiment.
Shipping Condition Packaging according to customer requirements(5mg, 10mg, 20mg and more). Ship via FedEx, DHL, UPS, EMS or other couriers with RT, or blue ice upon request.

Source of 15,16-Dihydrotanshindiol B

The roots of Salvia miltiorrhiza

15,16-Dihydrotanshindiol B Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

15,16-Dihydrotanshindiol B Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Preparing Stock Solutions of 15,16-Dihydrotanshindiol B

1 mg 5 mg 10 mg 20 mg 25 mg
1 mM 3.1817 mL 15.9084 mL 31.8167 mL 63.6335 mL 79.5418 mL
5 mM 0.6363 mL 3.1817 mL 6.3633 mL 12.7267 mL 15.9084 mL
10 mM 0.3182 mL 1.5908 mL 3.1817 mL 6.3633 mL 7.9542 mL
50 mM 0.0636 mL 0.3182 mL 0.6363 mL 1.2727 mL 1.5908 mL
100 mM 0.0318 mL 0.1591 mL 0.3182 mL 0.6363 mL 0.7954 mL
* Note: If you are in the process of experiment, it's necessary to make the dilution ratios of the samples. The dilution data above is only for reference. Normally, it's can get a better solubility within lower of Concentrations.

Organizitions Citing Our Products recently

 
 
 

Calcutta University

University of Minnesota

University of Maryland School of Medicine

University of Illinois at Chicago

The Ohio State University

University of Zurich

Harvard University

Colorado State University

Auburn University

Yale University

Worcester Polytechnic Institute

Washington State University

Stanford University

University of Leipzig

Universidade da Beira Interior

The Institute of Cancer Research

Heidelberg University

University of Amsterdam

University of Auckland
TsingHua University
TsingHua University
The University of Michigan
The University of Michigan
Miami University
Miami University
DRURY University
DRURY University
Jilin University
Jilin University
Fudan University
Fudan University
Wuhan University
Wuhan University
Sun Yat-sen University
Sun Yat-sen University
Universite de Paris
Universite de Paris
Deemed University
Deemed University
Auckland University
Auckland University
The University of Tokyo
The University of Tokyo
Korea University
Korea University
Featured Products
New Products
 

References on 15,16-Dihydrotanshindiol B

A novel multiplex polymerase chain reaction assay for detection of both HLA-A*31:01/HLA-B*15:02 alleles, which confer susceptibility to carbamazepine-induced severe cutaneous adverse reactions.[Pubmed:28884973]

HLA. 2017 Dec;90(6):335-342.

HLA-A*31:01 and HLA-B*15:02 have been widely reported to confer genetic susceptibility to carbamazepine (CBZ)-induced severe cutaneous adverse reactions (SCARs). Accordingly, the screening for these alleles has been highly recommended to prevent SCAR prior to introducing CBZ therapy. Although a number of methods are available for screening of HLA-A*31:01 or HLA-B*15:02 alleles separately, developing an assay that can detect both these alleles would be more clinically practical, cost-effective and less time-consuming. Therefore, in this study, a multiplex polymerase chain reaction (PCR) using TaqMan Probe was designed and validated to be able to detect HLA-A*31:01 and HLA-B*15:02. In comparison with Luminex-SSO/SBT/SSB, the multiplex PCR assay for detection of HLA-A*31:01 and HLA-B*15:02 had a perfect agreement in the validation group of 125 samples. The method was able to detect the target genes at the DNA concentration of 0.037 ng/muL. The unit cost of this assay is less than $5 USD with total time of 110 minutes.

Identification of the novel allele, HLA-B*15:388, in a Chinese bone marrow donor.[Pubmed:28963780]

HLA. 2018 Feb;91(2):135-136.

The novel allele, HLA-B*15:388, was identified in a Chinese bone marrow donor by sequence-based typing.

Knowledge and practices of chronic hepatitis B virus testing by general practitioners in Victoria, Australia, 2014-15.[Pubmed:28892601]

Aust Fam Physician. 2017 Sep;46(9):683-689.

BACKGROUND: More than one-third of people living with chronic hepatitis B virus (HBV) in Australia have not been diagnosed. The aim of this study was to assess general practitioners' (GPs') knowledge and practices regarding chronic HBV diagnosis, and identify opportunities to improve testing rates. METHODS: A cross-sectional survey was conducted with GPs working in Victoria, Australia. Statistically significant adjusted odds ratios for high knowledge, and ordering two or more HBV tests per week were calculated. RESULTS: Of 1000 GPs who were invited to participate, 232 completed the survey. Chronic HBV knowledge, use of interpreters, and awareness of HBV testing guidelines were low. Chronic HBV knowledge and testing were associated with age and graduation from a medical school outside Australia. Testing was also associated with gender. DISCUSSION: This study identified gaps in GPs' knowledge about chronic hepatitis. Several barriers to improving testing rates among at-risk populations were identified. We recommend revision of the guidelines for prevention in general practice, and educational activities to improve knowledge of at-risk populations for chronic HBV in Australia.

[Molecular characterization of non-vaccine Streptococcus pneumoniae serotypes 11A, 15 B/C and 23A recovered from invasive isolates in Colombia].[Pubmed:28968016]

Biomedica. 2017 Sep 1;37(3):390-396.

INTRODUCTION: A total of 192 invasive Streptococcus pneumoniae isolates, from serotypes 11A, 15B/C and 23A (not included in the conjugated vaccines), were collected in Colombia between 1994 and 2014 as part of the activities of the Network surveillance system for the causative agents of pneumonia and meningitis (SIREVA II). OBJECTIVE: To determine the molecular characteristics of invasive S. pneumoniae isolates from serotypes 11A, 15B/C and 23A in Colombia from 1994 to 2014. MATERIALS AND METHODS: The molecular characterization of the isolates was carried out through Pulse-Field Gel Electrophoresis (PFGE) and Multilocus Sequence Typing (MLST). RESULTS: Serotype 11A showed one clonal group represented by ST62. Serotype 15B/C was composed of three groups associated with Netherlands15B-37 ST199 (28.75%), ST8495 (18.75%), and SLV (Single-Locus Variant) of ST193 (21.25%). Isolates from serotype 23A were gathered in three clonal groups, with 70.21% closely related to ST42, 17.02% to Colombia23F-ST338, and 6.38% to Netherlands15B-37 ST199. CONCLUSION: Clones Colombia23F-ST338 and Netherlands15B-ST199 covered more serotypes than those previously found by other authors, including serotype 23A. These analyses reveal the importance of capsular switching in the spreading of successful clones among non-vaccine serotypes causing invasive pneumococcal disease.

Keywords:

15,16-Dihydrotanshindiol B,891854-86-7,Natural Products, buy 15,16-Dihydrotanshindiol B , 15,16-Dihydrotanshindiol B supplier , purchase 15,16-Dihydrotanshindiol B , 15,16-Dihydrotanshindiol B cost , 15,16-Dihydrotanshindiol B manufacturer , order 15,16-Dihydrotanshindiol B , high purity 15,16-Dihydrotanshindiol B

Online Inquiry for:

      Fill out the information below

      • Size:Qty: - +

      * Required Fields

                                      Result: